• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

What are the Long Term Effects of Estrogen-Only Therapy for Women with a Prior BSO?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Manson et al. (Ann Intern Med., 2019) compared estrogen therapy outcomes in women with and without bilateral salpingo-oophorectomy (BSO)

METHODS:

  • Subgroup analyses of the randomized Women’s Health Initiative (WHI) Estrogen-Alone Trial
  • Participants
    • Women aged 50 to 79 years with prior hysterectomy and known oophorectomy status
    • Treatment length median: 7.2 years
    • 18-year follow-up
  • Intervention groups
    • Conjugated equine estrogens (CEE) | 0.625 mg/d
    • Placebo
  • Primary outcomes: Measured during the intervention and follow-up
    • Coronary heart disease | Invasive breast cancer | All-cause mortality
    • A “global index”: Above endpoints with inclusion of
      • Stroke | Pulmonary embolism | Colorectal cancer | Hip fracture
  • Outcomes stratified by time of CEE initiation (by 10-year age groups)

RESULTS:

  • 9,939 women were included in this subgroup analysis
  • Overall, outcomes in the CEE arm did not differ significantly according to BSO status

Intervention Phase

  • Outcomes in CEE arm did differ by age during the intervention phase based on BSO status
    • ≥70 years and previous BSO: CEE was significantly associated with adverse effects
      • Global index hazard ratio (HR): 1.42 (95% CI, 1.09 to 1.86)
    • 50 to 59 years and 60 to 69 year brackets: Treatment effects were in the nonadverse direction
      • Global index: P trend by age = 0.016
      • Breast cancer: P trend by age = 0.010
    • Age did not impact outcomes in the non-BSO group

Cumulative Follow-Up (intervention and post-intervention phase)

  • Outcomes in CEE arm did differ during the intervention phase based on BSO status
    • 50 to 59 years with BSO
      • Treatment-associated reduction in all-cause mortality
      • Hazard ratio, 0.68 (95% CI, 0.48 to 0.96)
      • Most pronounced in women who had procedure <45 years
    • No BSO effect in older women (P trend by age = 0.034)
    • Age did not impact outcomes in the non-BSO group

CONCLUSION:

  • Overall, there was no effect of BSO on outcomes but when stratified by age, differing outcomes were seen in women with previous BSO
    • Women ≥70 had a greater risk for adverse effects during the treatment period

The authors state

This provides some reassurance to clinicians and their younger patients with BSO that, in the absence of contraindications, the use of estrogen beyond the average age of natural menopause to manage menopausal symptoms or—in women at high risk for fracture who cannot tolerate alternative osteoporosis therapies—to lower osteoporosis risk  should not have net adverse effects.

Learn More – Primary Sources: 

Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Learn More  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

North American Menopause Society: Hormone Therapy Statement
Does a Hysterectomy before 50 Shorten Lifespan?
The WHI Randomized Trials: Is Menopausal Hormone Therapy Associated with Long-Term Mortality?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site